Chapter

The clinical presentation and treatment of renal vasculitis

David Jayne

in Rheumatology and the Kidney

Second edition

Published on behalf of Oxford University Press

Published in print April 2012 | ISBN: 9780199579655
Published online February 2013 | e-ISBN: 9780191763472 | DOI: http://dx.doi.org/10.1093/med/9780199579655.003.0064

Series: Oxford Clinical Nephrology Series

The clinical presentation and treatment of renal vasculitis

Show Summary Details

Preview

1. Vasculitis is an avoidable cause of ESRD, and ESRD is usually the result of a delayed diagnosis. 2. ANCA-associated renal vasculitis is a common cause of unexplained acute renal failure in the elderly. 3. A prodromal phase of flu-like symptoms, weight loss and polymyalgia usually precedes a diagnosis of ANCA vasculitis by several months. 4. There should be a high index of suspicion for vasculitis in the presence of persisting unexplained constitutional symptoms or focal signs of inflammation, such as, arthritis, episcleritis or chronic ENT disease. 5. Active renal vasculitis is always accompanied by haematuria and proteinuria. Their absence reliably excludes this diagnosis. 6. Rituximab is an alternative induction therapy to cyclophosphamide, especially when treating relapsing or refractory disease. 7. Plasma exchange increases rates of renal recovery in severe presentations and is also used for alveolar haemorrhage. 8. Following successful remission induction, prolonged remission maintenance therapy is required to prevent relapse. Azathioprine is more effective than mycophenolate mofetil and preferable to methotrexate when there is renal impairment. 9. ANCA testing has a role in predicting relapse risk and a positive ANCA is more closely associated with relapse after treatment withdrawal.

Chapter.  7021 words.  Illustrated.

Subjects: Nephrology

Full text: subscription required

How to subscribe Recommend to my Librarian

Buy this work at Oxford University Press »

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.